BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock News

USA - NASDAQ:DRUG - CA10919W4056 - Common Stock

48.75 USD

-0.63 (-1.28%)

Last: 9/12/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DRUG Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Benzinga

Large Patient Population Is Key Driver For Bright Minds' Growth

11 days ago - By: Zacks Investment Research

Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?

4 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

a year ago - By: Benzinga

What's Going On With Bright Minds Biosciences Stock Friday?

4 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

5 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

6 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

7 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

7 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

7 months ago - By: MarketBeat - Mentions: BCTX RXRX

Biotechs on the Brink: 2 Stocks With Huge Potential

8 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

8 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

10 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

10 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

10 months ago - By: The Motley Fool

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month

10 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

10 months ago - By: Bright Minds Biosciences

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

a year ago - By: Bright Minds Biosciences

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

a year ago - By: Bright Minds Biosciences - Mentions: AIFF

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

a year ago - By: Bright Minds Biosciences

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

a year ago - By: Bright Minds Biosciences

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

a year ago - By: Bright Minds Biosciences

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

a year ago - By: Bright Minds Biosciences

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events